Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | PRKCA | P17252 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GALR3 | O60755 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756656 | 0.88 | TSHR (0.50) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL33456 | 0.83 | — | — | |
| SCHEMBL14088060 | 0.82 | TSHR (0.44) | TSHRPRKCACHRM2CHRM4CHRM1 | |
| SCHEMBL14088063 | 0.82 | TSHR (0.44) | TSHRPRKCACHRM2CHRM4CHRM1 | |
| SCHEMBL3909737 | 0.80 | LMNA (0.41) | TSHRPRKCACHRM2CHRM4CHRM1 | |
| SCHEMBL3909740 | 0.80 | LMNA (0.41) | TSHRPRKCACHRM2CHRM4CHRM1 | |
| SCHEMBL28482345 | 0.80 | LMNA (0.41) | TSHRPRKCACHRM2CHRM4CHRM1 | |
| SCHEMBL27638914 | 0.80 | TDP1 (0.48) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL19361541 | 0.79 | — | — | |
| SCHEMBL29120272 | 0.78 | CTSK (0.41) | TSHRPRKCACHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242897-A1 | Universal support media for synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004011474-A1 | UNIVERSAL SUPPORT MEDIA FOR SYNTHESIS OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242897-A1 | Universal support media for synthesis of oligomeric compounds | NEFM, POLRMT, POLM | TSHR 4495/4885PRKCA 4314/4885CHRM2 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.